Fluorouracil, also known by its abbreviated name 5FU, is a pyrimidine analog that works to inhibit thymidylate synthase, an important enzyme for DNA synthesis and cell division. By binding to thymidylate synthase, 5FU prevents the methylation of deoxyuridine monophosphate to thymidine monophosphate. Thymidine monophosphate is essential for DNA synthesis and its depletion causes DNA strands to terminate prematurely. As a result, 5FU selectively kills cells that are rapidly dividing such as cancer cells.

In addition to inhibiting thymidylate synthase, 5FU has other mechanisms of action that contribute to its anticancer effects. It can become metabolized to two active metabolites, fluorodeoxyuridine monophosphate and fluorouridine triphosphate, which get incorporated into RNA and DNA, respectively. This causes dysfunction of these nucleic acids and leads to cell death. 5FU may also enhance the anticancer effects of some cytotoxic drugs by strengthening intratumor concentration of these agents.

Uses in Cancer Treatment

Due to its ability to disrupt cancer cell proliferation, Fluorouracil (5FU) has been effectively used in chemotherapy regimens for a variety of malignancies. Some of its major clinical applications include:

Colorectal Cancer: As a single agent or in combination with other drugs like leucovorin, 5FU is a mainstay first-line treatment for colon and rectal cancers. Studies have shown that 5FU-based combinations can significantly improve response rates and survival outcomes compared to 5FU alone.

Gastroesophageal Cancer: Combination therapies containing 5FU along with cisplatin and either oxaliplatin or irinotecan are standard treatments for advanced gastric or esophageal adenocarcinoma. These regimens have demonstrated significant increases in median overall survival.

Breast Cancer: 5FU has activity against certain breast cancer subtypes when used with other chemotherapy medications like doxorubicin and cyclophosphamide in an AC-T regimen. This combination is a standard adjuvant treatment approach after surgical removal of the primary tumor.

Head and Neck Cancers: For patients with head and neck squamous cell carcinomas, 5FU is frequently combined with either cisplatin or carboplatin along with radiation therapy as definitive or adjuvant treatment. Studies support this multimodality approach improves survival rates versus radiation alone.